Nintedanib Slows Decline in FVC in Autoimmune Disease-Linked ILD
Subgroup analysis performed for patients with autoimmune disease-related progressive fibrosing interstitial lung diseases
Subgroup analysis performed for patients with autoimmune disease-related progressive fibrosing interstitial lung diseases
Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.
BI 1015550 is an investigational oral phosphodiesterase 4B inhibitor with combined antifibrotic and anti-inflammatory effects.
MVA-BN RSV consists of 5 distinct RSV antigens to stimulate a broad immune response against both RSV subtypes A and B.
Switching to dry powder inhaler more than halves carbon footprint of asthma treatment without asthma worsening
No association seen between GAS infections and tic onset among children with a first-degree relative with chronic tic disorder
Sabizabulin is a novel, oral cytoskeleton disruptor with both antiviral and anti-inflammatory properties.
The FDA has approved a 40mg prefilled syringe for Nucala (mepolizumab) as add-on maintenance treatment for children with severe eosinophilic asthma.
The application includes data from the two phase 3 studies, which evaluated the efficacy and safety of gefapixant in adults with refractory or unexplained chronic cough for at least 1 year.
Ryaltris is a metered, fixed-dose nasal spray that delivers 665mcg of olopatadine hydrochloride and 25mcg of mometasone furoate in each spray.